iTBS+D-Cycloserine for Youth Suicide

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2026

Conditions
Suicidal IdeationSuicide, AttemptedDepression, Anxiety
Interventions
DRUG

D-Cycloserine

Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.

DEVICE

intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation

Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).

DRUG

Placebo oral tablet

Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.

Trial Locations (1)

T2N 1N4

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
collaborator

University of Alberta

OTHER

lead

University of Calgary

OTHER